Algo version: 0.98b
BristolMyers Squibb is listed at the NYSE Exchange
BristolMyers Squibb [CELG-RI]
NYSE Sector: Healthcare Industry:Drug Manufacturers General

Is BristolMyers Squibb stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for BristolMyers Squibb 10 years ago, but if you had invested on Thursday 21st of July 2022 when the price was $0.155, you would have made a loss of $-0.109 per share or -70.14%

We do not have enough data to give you this answer.

BristolMyers Squibb has much of the business financed by loans. This puts the company at high risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.30, the company's ability to pay off the debt is normal. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for BristolMyers Squibb to be high [0.75 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.